Asia Fresh News

Asia Fresh Stories

Archive for November 14th, 2012

Join us for a Weekend of Experience, Creativity and Guidance at Startup Weekend Singapore, Women’s Edition

leave a comment »


Guys also Welcome

November 23rd, 24th, 25th
The Hub, Somerset Road

SINGAPORE, Nov. 12, 2012 /PRNewswire/ — Startup Weekend Women’s Edition, Singapore will bring together female entrepreneurs who have made their mark in the business world and showcase those who want to follow in their footsteps.

This is an exciting opportunity for aspiring entrepreneurs to collaborate and discover how to take a business from an idea to a prototype with support and advice from those who have done it!

Participants willspend 54 hours over a weekend, working in teams and practicing LEAN Startup methodologies to come up with an idea, a brand, marketing strategies and a pitch to deliver to the panel of expert judges.

What is Startup Weekend?

A global network of passionate leaders and entrepreneurs on a mission to inspire, educate and empower individuals, teams and communities. Startup Weekend has already taken place in 85+ countries, in 320+ cities (mostly USA, Canada and Europe). Startup Weekend Women’s edition will be a first for Singapore and is run in collaboration with The Next Women and The Athena Network Singapore.

Who are we looking for?

If you fit into one or more of these categories then this weekend is for you:

You want to experience a startup environment
You have an idea and want to get feedback and some different perspectives
You have expertise and would like to share it with others
You want different solutions for how to make your idea better/more scalable/more profitable
You want to get creative or learn about the business startup methodology
You have an existing business and you want to start a new venture
You are looking for a co-founder or team or resources to start a business with
You just want to come and join an action packed weekend and learn about starting up a business
Who will you be working with? Who will be mentoring you?

We’ve lined up an impressive array of judges and coaches to both mentor and grow your idea. These people are experts and pioneers in their respective fields and will be able to help with anything you might need.

Judges include:

Benjamin Lee (Founder and CEO, Entrepid), Elizabeth Tan (Managing Director, Heatwave Shoes), Grace Sai (Co-founder, The Hub Singapore), Rina Neoh (Co-founder, Mercatus Capital Pte Ltd)

Mentors include:

Charlotte Ong (Chief Entertainment Officer, Digital Boomerang), Christel Quek (Global Social Marketing Manager, Havas Media), Dave Rogers (Visionary Business Coach & Long Term Investor), Gobbs Lim (Creative Daydreamer, Brew Creative), Gwendolyn Regina Tan (CEO, SGE), Jin Zwicky (VP Customer Experience, OCBC Bank), Kristine Lauria (Digital Media Consultant, Mission Street Media), Min Xuan Lee (Co-founder, Playmoolah), Neethu Stephen (COO, Servolve Pte.Ltd), Sarah Cheng-De Winne (Business Development Director, Relay Room), Simon Dale (Head of Technology and Innovation, Asia Pacific Japan at SAP), Vicki Lew (Firestarter, Brew Creative)

Click here to read more about this extraordinary team.

Ready to join us?

This edition of Startup Weekend invites up to 100 ladies (and men) to bring their energy, ideas and creativity to build something big over the weekend. We provide the working space, brain fuel, food, mentors, new friends, and inspiring speakers and judges.

Would you like to sponsor Startup Weekend Women’s Edition?

Our global sponsors include, Microsoft Bizpark, Google, .CO, Sendgrid, and CloudMine. If you would like be a local sponsor, please contact the organisers.

Date & Time: From 6.30pm on Friday 23rd November to 9pm on Sunday 25th November
Price: S$99 special ticket price using the PR Newswire priority code: PRNews
Venue: Hub Singapore, National Youth Council Academy, 113 Somerset Road, 238165
Follow the buzz on Twitter: #SGWSW
Contact the organisers:
Learn more:
Connect with participants on the Facebook event page:

Read about previous Startup Weekends:

Gina Romero
Managing Director The Athena Network Singapore and APAC
Tel: +65 8511 6912

SOURCE The Athena Network Singapore

Written by asiafreshnews

November 14, 2012 at 5:58 pm

Posted in Uncategorized

GREE is First Japanese Digital Content Provider to Use Zong to Get Paid by Billions of Mobile Subscribers Worldwide

leave a comment »

TOKYO, Nov. 14, 2012 /PRNewswire/ — PayPal Pte. Ltd. today announced that GREE, Inc., a leading global mobile social gaming company, is the first digital content provider in Japan to use Zong as its global carrier bill payment service to reach billions of users on 166 mobile carriers in 40 countries. With Zong, GREE can conveniently and securely accept payments for digital goods purchases from international users of GREE Platform through direct mobile carrier billing.

Zong is an established global carrier payment service used by Zynga and Facebook and other digital content providers worldwide. With Zong, digital goods merchants can accept payments globally from mobile users, even from consumers who do not have a bank account or credit card. Zong first verifies the mobile phone number and account in a matter of seconds, and then adds the payment to the customer’s mobile phone bill. Because of its frictionless, easy-to-use payment experience, Zong contributes to increased conversion rates compared to traditional payment methods, like credit cards.

“Zong is a revolutionary service that provides fast, easy carrier payment to billions of mobile users worldwide,” said Shintaro Aikawa, Senior Vice President, Business Operations, GREE, Inc. “We’re excited to be bringing Zong to our overseas users through our strategic partnership with PayPal. With this enhanced convenience and flexibility of payment that Zong enables, we’re confident we can make GREE Platform more accessible and more fun to use for mobile gamers around the world.”

“We are thrilled to expand our business alliance with GREE to provide both PayPal and Zong as faster, safer payment services for millions of international users of GREE Platform,” said Jonathan Epstein, General Manager, and Branch Representative PayPal Pte. Ltd. Tokyo Branch. “With global consumer spending on digital goods expected to increase to USD367 billion in 2016*, we look forward to enabling more leading digital content providers in Japan to reach a worldwide audience and grow their overseas business.”

About PayPal

PayPal is the faster, safer way to pay and get paid online, via mobile devices and in store. The service allows people to send money without sharing financial information, with the flexibility to pay using their account balances, bank accounts, credit cards or promotional financing. With more than 117 million active accounts in 190 markets and 25 currencies around the world, PayPal enables global commerce. PayPal is an eBay (NASDAQ:EBAY) company. PayPal is headquartered in San Jose, Calif. and its international headquarters is located in Singapore. More information about the company can be found at


At present, bank accounts are not available as a funding source in some countries and territories including Japan.
At present, promotional financing is not available as a funding source in some countries and territories including Japan.
*Source: Gartner

Media Contacts

Dickson Seow Kyohei Suzuki / Icho Saito
PayPal Asia Pacific The Hoffman Agency Japan
Tel: +65-6510-6463 Tel: +81-3-5159-5750
Email: Email:

Written by asiafreshnews

November 14, 2012 at 4:06 pm

Posted in Uncategorized

Campari to Kiss Superstition Goodbye in 2013 Calendar!

leave a comment »

MILAN, Nov. 13, 2012 /PRNewswire/ — Taking the lead in this year’s Campari Calendar is beautiful Oscar winning actress, Penelope Cruz, whilst noted fashion photographer, Kristian Schuller, shot the intense imagery.

To view the Multimedia News Release, please click:

Set to take the audience on a stunning visual voyage, the 2013 Calendar showcases Campari’s latest female protagonist in 13 vivid shots, as she engages with intriguing and mystical superstitions, such as black cats, broken mirrors and walking under ladders. Dressed in a variety of gorgeous red-themed dresses and shoes from top fashion houses including Vivienne Westwood and Ferragamo, as well as jewellery by Chopard, Penelope dazzles in every shot.

On starring in the Campari 2013 Calendar, Penelope Cruz comments: “I have really enjoyed starring in the Campari Calendar 2013, I found the superstitious theme extremely intriguing and stimulating. It’s been a pleasure to work with such a talented and professional team, particularly Kristian Schuller, the Calendar photographer, since I really admire his work.”

Internationally celebrated fashion photographer Kristian Schuller shot the Campari Calendar for its 14th edition. Renowned for telling curious stories through his work, and with his love of surreal imagery, Kristian perfectly captured the theme of the Calendar through his cutting-edge photography style.

On shooting the Campari Calendar 2013, Kristian Schuller comments: “The Campari Calendar is synonymous with outstanding style and creative edge, and being able to transform these generic stereotypes into powerful and magical images has been a joy.”

Penelope is the latest star in the iconic Campari Calendar. She joins some of the world’s most stunning women who have adorned the pages of previous Campari Calendars including, Salma Hayek, Eva Mendes, Jessica Alba and Milla Jovovich.

Bob Kunze-Concewitz, CEO of Gruppo Campari, comments: “For the 2013 Calendar, our intention was to represent the power of confidence in believing you can defy anything, and kiss goodbye to superstitions such as broken mirrors and mystical black cats. It is our mission to offer Campari lovers an intense, pleasurable moment to celebrate confidence and the magic power of the number 13. ”

The concept of Kiss superstition Goodbye was created by BCube Milan. Working side by side with the photographer Kristian Schuller on the project were Andrea Marzagalli, senior art director and Bruno Vohwinkel, senior copywriter. The production has been executed L&A Artist – Milan.

Written by asiafreshnews

November 14, 2012 at 11:52 am

Posted in Uncategorized

Landmark Phase III Study of Bayer’s Xarelto(R) (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery Disease

leave a comment »

BERLIN, Nov. 13, 2012/PRNewswire/ —

Not intended for U.S. and UK Media

20,000-patient study will be conducted in collaboration with Population Health Research Institute
Composite of cardiovascular death, myocardial infarction and stroke as primary efficacy endpoint
Rivaroxaban is the first novel oral anticoagulant under assessment in this high risk patient population
Bayer HealthCare announced today the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto® (rivaroxaban) to date, investigating the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).

To view the Multimedia News Release, please click:

The Phase III study COMPASS will assess the potential of rivaroxaban to provide important additional protection to patients when added to aspirin as compared to rivaroxaban and aspirin as single treatments. The study will be conducted in collaboration with the Population Health Research Institute (PHRI) and will enroll approximately 20,000 patients from more than 450 sites across more than 25 countries worldwide.

“Today, aspirin is the gold standard and provides significant protection for patients with coronary or peripheral artery disease. However, a residual risk of cardiac events such as heart attack, stroke or even death remains in these high-risk patients,” said Dr. Salim Yusuf, Executive Director of the PHRI, Canada, and Principal Investigator of the COMPASS study. “This is therefore an important study, designed to provide significant insights on additional, potentially complementary, cardioprotective benefits of rivaroxaban for these patients.”

In CAD and PAD, the inner wall of the arteries progressively thickens due to accumulation of lipids, calcification and cell proliferation. This plaque narrows the arteries and decreases the amount of blood flow to the heart muscle or the legs. This process is called atherosclerosis. If plaque from the wall of an artery ruptures, a blood clot can form at the site of the rupture leading to serious events including myocardial infarction, stroke or even death.

Currently, the most commonly prescribed treatments for the prevention of MACE in CAD and PAD patients are antiplatelet agents such as aspirin – a product with a well documented role in the prevention of cardiovascular events across a broad range of patients.

“Antiplatelet therapies and rivaroxaban have complementary mechanisms of action and when combined have been shown to improve outcomes in patients with acute coronary syndrome. In the same way, COMPASS will evaluate whether the combination has the potential for more complete protection against long-term clot formation in patients with CAD and PAD in comparison to each of the products alone,” said Dr. Kemal Malik, Member of the Bayer HealthCare Executive Committee and Head of Global Development.

About the Burden of Coronary and Peripheral Artery Disease

Coronary artery disease (CAD) is the most common cause of cardiovascular disease and is responsible for approximately 7.3 million deaths worldwide every year. One-third to one-half of all middle-aged men and women in high income countries are at risk of developing CAD during their lifetime, and the number of people with CAD is rising globally. By 2020, the burden of coronary artery disease is projected to reach 82 million disability-adjusted life years (DALYs) or “healthy years of life lost”.

Peripheral artery disease (PAD), while often undiagnosed, affects over 27 million people in Europe and North America and is a powerful risk marker of cardiovascular disease. Globally, screening studies suggest that approximately 20% of adults older than 55 years have evidence of PAD. The disease prevalence is strongly age-related and, like CAD, the numbers of affected patients is rising, because of the aging of the population.


The Phase III study COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) will include approximately 20,000 patients from more than 450 sites across more than 25 countries worldwide. Patients with documented atherosclerosis related to CAD or PAD will be enrolled into the study. The primary efficacy endpoint is a composite of cardiovascular death, myocardial infarction and stroke. The primary safety endpoint is major bleeding. In the study, patients will be randomized to receive either rivaroxaban 2.5 mg twice-daily in addition to aspirin 100 mg once-daily, rivaroxaban 5 mg twice-daily alone, or aspirin 100 mg once-daily alone. The study will be conducted by the Population Health Research Institute (PHRI), a leading academic health science research organization based in Hamilton, Ontario, Canada.

About the Population Health Research Institute (PHRI)

PHRI is a world-leading academic health science research institute focused on improving global health outcomes. Based in Hamilton, Ontario, Canada, its research interests are global and include a broad spectrum of health-related issues. Originally a cardiovascular disease research institute, PHRI’s programmes have expanded to include a broad range of medical and societal conditions in varied populations defined by ethnicity and/or geographic region. To date, PHRI has conducted more than 50 global trials and epidemiological studies in more than 1,500 centres in 83 countries, involving over 500,000 patients. More information can be found at

About Venous Arterial Thromboembolism (VAT)
Thrombosis is the formation of a blood clot inside a blood vessel, blocking a vein (venous thrombosis) or artery (arterial thrombosis). Venous Arterial Thromboembolism (VAT) is caused when some or all of a clot detaches and is moved within the blood stream until it obstructs a smaller vessel. This can result in damage to vital organs, because the tissue beyond the blockage no longer receives nutrients and oxygen.

VAT is responsible for a number of serious and life threatening conditions:

Venous Thromboembolism (VTE) occurs when part of a clot formed in a deep vein, for example in the leg (known as deep vein thrombosis, or DVT), is carried to the lung, via the heart, preventing the uptake of oxygen. This is known as a pulmonary embolism (PE), an event which can be rapidly fatal
Arterial Thromboembolism occurs when oxygenated blood flow from the heart to another part of the body (via an artery) is interrupted by a blood clot. If this occurs in a vessel supplying blood to the brain, it can lead to a stroke, an event that can be severely debilitating or fatal. If it occurs in a coronary artery, it can lead to acute coronary syndrome (ACS), a complication of coronary heart disease which
includes conditions such as myocardial infarction (heart attack), and unstable angina
VAT is responsible for significant morbidity and mortality, and requires active or preventative treatment to avoid potentially serious or fatal patient outcomes.

To learn more about VAT, please visit

About Xarelto® (Rivaroxaban)

Rivaroxaban is the most broadly indicated new oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto is approved for use in the following venous arterial thromboembolic (VAT) indications:

The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors in more than 70 countries worldwide
The treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) in adults in more than 70 countries worldwide
In the U.S. also for the treatment of pulmonary embolism and prevention of recurrent PE and DVT in adults
The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery in more than 120 countries worldwide
Since the first approval of Xarelto in 2008, more than two and a half million patients worldwide have now received Xareltoin daily clinical practice.

Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).

Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient.

Responsible use of Xarelto is a high priority for Bayer, and the company has developed a Prescribers Guide for physicians and a Xarelto Patient Card for patients to support best practices.

To learn more, please visit:

To learn more about thrombosis, please visit

To learn more about Xarelto, please visit

About Aspirin®

Acetylsalicylic acid, the active ingredient in Aspirin®, has been extensively investigated in more than 200 studies involving more than 200,000 patients across varying levels of cardiovascular (CV) risk. Given the existing body of clinical evidence, low-dose aspirin use in appropriate patients is approved by regulatory authorities around the world for CV event prevention, and supported by major evidence-based clinical guidelines, including those of the American Heart Association and American College of Cardiology, European Society of Cardiology, and American College of Chest Physicians.

Based on its proven efficacy, safety and cost-effectiveness, low-dose aspirin continues to be the standard of care for reducing heart attacks and ischemic strokes in patients with established CV disease. Additionally, in more than 50 countries around the world, low-dose aspirin is approved for use in the primary prevention of CV events in appropriate at risk patients. When used as directed by a physician, low-dose aspirin is infrequently associated with clinically significant side effects. Serious bleeding rarely occurs. Gastro-intestinal bleeding (GI) has been shown to occur in less than 1% of those taking aspirin to prevent a recurrent CV event; serious GI or extracranial bleeding events are expected in less than 1/10th of one percent (3 in 10,000 people per year) patients taking low-dose aspirin for primary prevention(1). Bayer supports the use of aspirin for primary prevention only in those markets where the indications have been approved.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. More information at

Our online press service is just a click away:

Information for editors:

For full multimedia release, including additional material such as videos and backgrounders, please visit

Find more information at

sp (2012-0498E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


1. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised clinical trials. The Lancet 2009; 373:1849-1860


Written by asiafreshnews

November 14, 2012 at 11:26 am

Posted in Uncategorized

Interstate China Hotels & Resorts AppointsTimur Senturk Managing Director of J Hotel at Shanghai Tower in China

leave a comment »

SHANGHAI/PRNewswire/ — Interstate China Hotels & Resorts Company Limited (“Interstate China”) today announced that Timur Senturk has been appointed Managing Director of China’s tallest ultra luxury hotel, the flagship J Hotel located at Shanghai Tower. Currently under construction in Shanghai’s central business district of Lujiazui, Pudong, The J Hotel Shanghai Tower is anticipated to open in the fourth quarter of 2015 and will be operated by Interstate China Hotels & Resorts, a joint venture between Shanghai Jin Jiang International Hotels Company Limited (“Jin Jiang Hotels”), China’s leading hotel operator and developer, and U.S.-based Interstate Hotels & Resorts.
A seasoned general manager with global experience, Senturk comes to his new assignment from 12 years with The Ritz-Carlton Company where he most recently was general manager of the Ritz-Carlton Guangzhou, China. Prior to his assignment in China, he was general manager for the Ritz-Carlton hotels in South Beach Miami, FL, and Pentagon City, Washington, D.C. Throughout his 23-year career, Senturk also has operated hotels in India, Thailand and the U.K.
“Timur is exactly the kind of international hotelier essential to leading the flagship hotel for a new, world-class luxury brand and introducing The J Hotel Shanghai Tower to an international audience,” said Jim Abrahamson, Interstate’s chief executive officer. “His experience in every area of luxury hotels, coupled with twelve years with Ritz-Carlton, makes him an outstanding choice to establish a new benchmark in luxury hotels in China.”
The J Hotel Shanghai Tower, anticipated to open with over 200 luxurious guestrooms in the fourth quarter of 2015, is the new and innovative ultra-luxury brand from Jin Jiang Hotels, the leading hotel group in China. The lobby will be located on the 101st floor of Shanghai Tower, with the hotel situated within floors 84-111. The hotel will feature three dynamic restaurants and a world-class spa. The J Brand itself, created by a steering committee of international and domestic Chinese hospitality experts, will offer its guests unparalleled experiences in hospitality and service.
Upon completion, Shanghai Tower will be China’s tallest building and the second tallest in the world, rising 121 stories (2,073 feet; 631 m) with a gross floor area (GFA) of more than six million square feet. The Shanghai Tower symbolizes modern China and will be the world’s tallest LEED-certified structure, a “vertical city” providing every facility and amenity, it will set new standards in design.
About Interstate China Hotels & Resorts
Shanghai-based Interstate China Hotels & Resorts, a joint venture between Interstate Hotels & Resorts and Jin Jiang Hotels, was established in 2010 as the first international third-party hotel management company to enter China. The Company’s management platform provides hotel owners and developers with the resources and economies of scale necessary for world-class operations of franchised hotels under leading international brands and landmark independent hotels. Over 50 years of world class management experience and proven success for owners enable Interstate China to instill international hotel management policies, procedures and systems into China’s market. Since tapping into China’s market in 2010, Interstate China has signed management agreements with 10 hotels, of which, four have already opened for operation, the remaining six are expected to commence operation in 3 years’ time. Interstate China’s goal is aligned with owners’ goals to enhance bottom line profitability and return on investment. Currently, Interstate China has more than 3,700 rooms throughout the country. For more information about Interstate China Hotels & Resorts, please visit
About Jin Jiang Hotels
Shanghai Jin Jiang International Hotels (Group) Company Limited is one of the leading hotel operators and managers in China and its stock was listed on the Main Board of Hong Kong Stock Exchange. Currently, over 900 hotels of the Group including star-rated hotels and Jin Jiang Inn Budget Hotels are under operation and development, providing nearly 136,000 rooms across more than 200 cities and towns in 31 provinces, autonomous regions and municipalities throughout China. The Group’s overseas business mainly comprises of its 50% interest in IHR Group, which manages around 400 hotel properties across 9 countries all over the world. The Group also has equity interests in three Chinese listed companies, namely Jing Jiang Hotels, Jinjiang Investment and Jinjiang Travel. For more information about the Company, please visit its website:
About Interstate Hotels & Resorts
Interstate Hotels & Resorts, Inc., a wholly-owned subsidiary of a 50/50 joint venture between subsidiaries of Thayer Lodging and Jin Jiang Hotels, is the leading U.S.-based global hotel management company, operating branded full- and select-service hotels and resorts, convention centers and independent hotels worldwide. Interstate and its affiliates manage 367 hotels with 69,000 rooms in North America, Europe and Asia-Pacific, including seven wholly owned hotels. In addition, Interstate has executed agreements to manage 36 hotels with more than 7,600 rooms under construction or development throughout the world. For more information, visit
About The Thayer Group
The Thayer Group (“Thayer”) is a US-based private equity firm with a lengthy and successful track record. Founded in 1991, it has consistently provided returns for its hospitality funds. Across its portfolio, Thayer has funds covering key asset classes (“Thayer Lodging RE Funds,” “Thayer China Opportunity PE Fund,” and “Thayer Ventures VC Fund”). Thayer first entered China in 2005 with its investment in Shanghai-based HUBS1. This has proved to be rewarding. The HUBS1 CRS system is now the leading web-based, real-time, Central Reservation System in today’s market, which provides client hotels a one-stop seamless connection to all major Global Distribution System (GDS) companies, hundreds of third-party websites, travel agencies and corporations. In 2010, Thayer created a 50/50 joint venture with Shanghai Jin Jiang International (Group), Company Limited to privatize Interstate Hotels & Resorts, Inc. Since the acquisition, the company’s management contracts have increased 34%. For more information on Thayer in China, please contact
Source: Interstate China Hotels & Resorts Company Limited

Written by asiafreshnews

November 14, 2012 at 11:18 am

Posted in Uncategorized

Tagged with

Bushmills Irish Whiskey(R) Partners With Lowden(R) to Create Handcrafted Whiskey Barrel Oak Guitars

leave a comment »

BUSHMILLS, Northern Ireland /PRNewswire/ — Bushmills Irish Whiskey, which has been handcrafted on the North Coast of Ireland for centuries, has partnered with world famous luthier, George Lowden, to create three special-edition guitars, handmade from barrel-oak used in the whiskey making process.

(Photo: )
(Photo: )
(Photo: )
(Photo: )

Bushmills Irish Whiskey and George Lowden Guitars are both world-renowned brands from Northern Ireland. George and his team have handmade guitars for some of most famous names in music, including Eric Clapton, Van Morrison and The Edge.
The guitars were presented to singer-songwriter Foy Vance and other artists as a thank-you for their participation in Bushmills Live, the handcrafted whiskey and music festival which took place at the Old Bushmills Distillery in June 2012, headlined by Snow Patrol.
The guitar-making process took more than three months. Each barrel stave had to be carefully sanded by hand then painstakingly glued together to create panels which were then hand-cut by George Lowden to guitar templates he has been using for almost 40 years.
Finally, the team at Lowden assembled the guitars, incorporating the whiskey barrel oak into traditional Lowden body designs.
George Lowden said: “Making any guitar by hand is highly challenging but it was an enormous privilege to work with such special wood and it took us a considerable amount of time to create them. However, what we have managed to do is create something quite special. We were delighted that the musicians were so pleased with them.”
Bushmills Master Distiller, Colum Egan, said: “To see barrels that have housed our whiskey being used in this way is remarkable. Their creation celebrates the handcrafted qualities at the heart of both Bushmills and Lowden Guitars and I want to thank George and his team for making them.”
To download a full gallery of the ‘making-of’ the guitars, click on this link:
Share Bushmills Responsibly
The BUSHMILLS words, BLACK BUSH, 1608, the Pot Still device and associated logos are trademarks ©The ‘Old Bushmills Distillery’ Co. Limited 2012.
Source: Bushmills Irish Whiskey

Written by asiafreshnews

November 14, 2012 at 10:50 am

Posted in Uncategorized

RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer

leave a comment »

FORT WASHINGTON, Pa., Nov. 13, 2012 /PRNewswire/ — ReSearch Pharmaceutical Services, Inc. (RPS), a next generation CRO that provides comprehensive global Phase 1-4 clinical development solutions to the biopharmaceutical and medical device industries, today announced that Jonathan M. Fishbein, M.D. has joined the organization as Executive Vice President and Chief Medical Officer.

In his role, he will have the responsibility of providing leadership and strategic direction to the Medical, Safety, and Medical Writing departments. Dr. Fishbein has extensive experience in the planning and execution of clinical research in a broad range of therapeutic areas.

Dr. Fishbein joins RPS having recently served as a Vice President in several medical and scientific capacities at ICON Clinical Research.

Dr. Fishbein has over 20 years experience in clinical and basic research, working in the CRO industry, as well as the Government, academic and non-profit sectors. Before joining ICON, he simultaneously held the positions of Special Assistant to the Deputy Director of the National institute of Allergy and Infectious Diseases (NIAID) and Senior Fellow at the International Center for Research on Women. Prior to those positions, he served as the first Director of the Office for Policy in Clinical Research Operations (OPCRO) at the NIAID’s Division of AIDS. In that role, Dr. Fishbein enforced compliance with regulations, guidance and policies to assure that federally-funded clinical research in HIV/AIDS met established standards of quality, integrity and ethics to protect the safety, rights, and confidentiality of human research subjects.

Before government service, he held various roles at PAREXEL International Corporation, including Vice President of North American Medical Services.

A surgeon by training, Dr. Fishbein was a Medical Staff Fellow at the National Cancer Institute (Immunology Branch) and a Fellow in Transplantation Immunology at the Transplantation Biology Research Center at the Massachusetts General Hospital/Harvard Medical School.

“Jonathan brings significant expertise to RPS, and we are extremely pleased to welcome him as a member of our Executive Management Team. His addition builds on the depth and breadth of our strategic medical affairs leadership, and allows RPS to continue the growth of our global drug safety organization,” said Alan Morgan, Chief Operating Officer.

About RPS

RPS provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries. By combining our highly experienced clinical research operations infrastructure with the industry’s largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from globally Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project teams providing innovative, seamless, cost-effective and high quality services.

With more than 5,000 employees, RPS operates in more than 64 countries across the globe.

Written by asiafreshnews

November 14, 2012 at 10:49 am

Posted in Uncategorized

Fifty Shades Social has Just Gone Live

leave a comment »

BIRMINGHAM, England /PRNewswire/ — The Phenomenal Fifty Shades Trilogy has blown all other sensualised Book Sales records out of the bedroom, into oblivion.
Fifty Shades has created a huge impact with its portrayal of the raunchy relationship between Ana and Christian. The books have created a phenomenon that the world has never seen before and a new meaning to erotic literature which is being read openly by both sexes. The success has created a universal desire to continue with the emotions and memories awoken by the sensational storyline of two lovers both dominating and surrendering to each other.
E.L. James has released the genie from the bottle and fans are now showing their allegiance buying branded items, attending Fifty Shades Festivals, Fashion Shows and Events.
The demand to communicate with like minded people was inevitable and has been launched to provide fans with an exciting online site through which to communicate and connect at any time. is the online Appreciation and Fan site for Supporters of the Trilogy which has changed the thoughts and lives of many people, transporting both male and female readers to a world of fantasy, exploring relationships, minds, bodies and more adventurous sexuality. Some say their experiences since reading books have helped to save their relationships. Married or Single, Male or Female or as a Couple or Group, you are welcome to join
It’s free to join and fun to be involved and see what others are thinking and planning to spice up their relationships. will offer you great access to like minded people so making friends with individuals, groups and clubs couldn’t be easier or more fun.
It can also be anonymous so choose your avatar and blog your dreams and desires to experience a few moments of fantasy whenever you need it.
“When it’s time to release inner emotions and pent up desires go to and explore your inner self, shedding inhibitions and expanding your mind, playing, having fun, sharing Experiences, Desires, Secrets and Ambitions!” Visitors can up-load images and videos under the guideline, sensual rather than sexual.
Isn’t it time to find out who we are, how we feel and get mentally and physically stimulated? There are rules and regulations for everyone on the site but you will be setting most of them so go for it and join today!
Contact details:, +44(0)7884123123, +44(0)7714660898

Written by asiafreshnews

November 14, 2012 at 10:03 am

Posted in Uncategorized